The prognosis of chronic myeloid leukemia (CML) has changed during the past decades from a disease with an overall survival of only 5 years to one in which patients can enjoy a near normal life-expectancy.
Currently, there are five TKIs available for CML treatment in clinical practice. Imatinib and the second-generation TKIs nilotinib, dasatinib, and bosutinib are approved in newly diagnosed CM patients whereas ponatinib is a third-generation TKI approved for second line treatment or in patients harboring the BCR-ABL1T3151 mutant…